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Factor XIIIA Transglutaminase Crosslinks
AT1 Receptor Dimers of Monocytes at the
Onset of Atherosclerosis
and of related cardiovascular disorders (Ljungman et al.,
1983; Widgren et al., 1992). Moreover, the involvement of
the angiotensin II-AT1 system in the pathogenesis of
essential hypertension and of vascular disease is well
established (Schiffrin, 2002). Remarkably, hypertensive
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2 Institut fu¨r Pharmakologie patients display an enhanced angiotensin II-dependent
monocyte activation and adhesion to endothelial cellsVersbacher Straße 9
D-97078 Wu¨rzburg that are still not understood (Do¨rffel et al., 1999, 2001).
Since an enhanced monocyte adhesiveness may sensi-Germany
tize hypertensive patients to the development of athero-
sclerosis (Do¨rffel et al., 2001; Dzau, 2001), we investi-
gated mechanisms accounting for the enhanced AT1Summary
responsiveness of monocytes.
Receptor homo- and heterodimerization specificallyMany G protein-coupled receptors form dimers in cells.
However, underlying mechanisms are barely under- modify signaling of individual receptor subtypes. There-
fore, we sought to investigate the involvement of re-stood. We report here that intracellular factor XIIIA
transglutaminase crosslinks agonist-induced AT1 recep- ceptor dimerization in the enhanced angiotensin II re-
sponsiveness of monocytes. The AT1 receptor formstor homodimers via glutamine315 in the carboxyl-ter-
minal tail of the AT1 receptor. The crosslinked dimers heterodimers with various other receptors, such as the
bradykinin B2 receptor (AbdAlla et al., 2000), the angio-displayed enhanced signaling and desensitization
in vitro and in vivo. Inhibition of angiotensin II release tensin II AT2 receptor (AbdAlla et al., 2001a), the 2-
adrenergic receptor (Barki-Harrington et al., 2003), andor of factor XIIIA activity prevented formation of cross-
linked AT1 receptor dimers. In agreement with this the dopamine D1 receptor (Zeng et al., 2003). Heterodi-
merization of the AT1 receptor with the B2 receptor en-finding, factor XIIIA-deficient individuals lacked cross-
linked AT1 dimers. Elevated levels of crosslinked AT1 hances specifically angiotensin II-stimulated signaling
of preeclamptic patients (AbdAlla et al., 2001b). Thisdimers were present on monocytes of patients with
the common atherogenic risk factor hypertension and event does not seem to contribute to the enhanced
angiotensin II responsiveness of monocytes, becausecorrelated with an enhanced angiotensin II-dependent
monocyte adhesion to endothelial cells. Elevated lev- monocytes do not express significant amounts of B2
receptors. The AT1 receptor is also reported to formels of crosslinked AT1 receptor dimers on monocytes
could sustain the process of atherogenesis, because homodimers (AbdAlla et al., 2001a, 2001b). GPCR homo-
dimerization may affect receptor signaling as well asinhibition of angiotensin II generation or of intracellular
factor XIIIA activity suppressed the appearance of receptor internalization or cell surface targeting. Analy-
sis of the enhanced AT1-dependent activation of mono-crosslinked AT1 receptors and symptoms of athero-
sclerosis in ApoE-deficient mice. cytes led us to identify hyperresponsive crosslinked AT1
receptor homodimers triggered by angiotensin II and
the transglutaminase activity of intracellular factor XIIIA.Introduction
We herein present strong evidence that the species of
crosslinked AT1 dimers contributes to an enhancedG protein-coupled receptors (GPCRs) comprise the
largest family of cell surface membrane receptors and monocyte adhesiveness of hypertensive patients and
thereby may sustain the process of atherogenesis bymediate a panoply of different physiological functions.
Although GPCRs have long been considered to function chronic sensitization of circulating monocytes.
as monomers, increasing evidence suggests that homo-
and heterodimerization are characteristic features of Results
this receptor family. Homo- and heterodimerization of
GPCRs regulate many receptor-specific functions such Monocyte Activation in Humans
as ligand binding, signaling, desensitization, and cell To analyze mechanisms accounting for an enhanced
surface targeting (Franco et al., 2003; Terrillon and Bou- AT1-dependent monocyte activation in essential hyper-
vier, 2004). Yet, little is known about the pathophysiolog- tension, we determined the release of interleukin-1 as
ical relevance of GPCR dimerization in vivo. an activation marker of circulating monocytes, enhanc-
We previously detected increased levels of AT1/B2 re- ing monocyte-endothelial cell adhesion. The basal and
ceptor heterodimers on platelets and vessels of pre- the angiotensin II-stimulated release of interleukin-1
eclamptic women. These dimers seem to contribute to were significantly increased in hypertensive patients
the enhanced angiotensin II responsiveness of this hy- compared to the healthy controls (Figures 1A and 1B).
pertensive disorder (AbdAlla et al., 2001b; Quitterer et The enhanced release of interleukin-1 was mediated
al., 2004). An enhanced angiotensin II responsiveness by the angiotensin II AT1 receptor, as evidenced by the
is also a prominent feature of essential hypertension inhibition with the AT1-specific antagonist losartan (Fig-
ures 1A and 1B). For comparison, the release of interleu-
kin-1 after stimulation of the monocytic ETA receptor*Correspondence: toph029@rzbox.uni-wuerzburg.de
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Figure 1. Increased Monocyte Activation and
Covalently Bonded AT1 Dimers of Hyperten-
sive Patients
(A and B) Basal (A) and angiotensin II-stimu-
lated (B, ang, 10 nM) release of interleukin-
1 from monocytes of eight healthy control
individuals (controls) and eight hypertensive
patients (patients). The AT1-specific antago-
nist losartan (5 M) was added as indicated
( antag.; *p  0.02 versus controls).
(C and D) Basal and angiotensin II-stimulated
adhesion of monocytes to endothelial cells
determined with monocytes of the eight con-
trols and of the eight patients (*p  0.02 ver-
sus controls).
(E) Specificity of the antibodies for AT1 was
controlled with HEK cells expressing the AT1
receptor (lane 1,) or with mock-transfected
cells (lane 2, ).
(F) Increased levels of SDS-stable AT1 recep-
tor homodimers on monocytes of the eight
patients compared to the eight controls. The
AT1 receptor was detected in immunoblot of
monocytic membranes with affinity-purified
AT1-specific antibodies (IB, anti-AT1). Arrow-
heads mark receptor monomers (M ) and ho-
modimers (D ). The lane marked with a is a
specificity control performed in the presence
of the corresponding antigen used for immu-
nization.
(G) Immunoblot of affinity-purified monocytic
dimeric AT1 receptor isolated from patients
(left panel). N-terminal protein sequencing of
the protein yielded solely the AT1 receptor
sequence (right panel).
by endothelin-1 was not significantly different between another vascular disorder, preeclampsia, is due to al-
tered AT1/B2 receptor heterodimerization (AbdAlla et al.,controls and patients (312  57 pg/105 cells, n  8,
versus 310  63 pg/105 cells, n  8; data not shown). 2001b). But AT1/B2 receptor heterodimerization does not
seem to play a major role in enhancing monocyte activa-Thus, there is an increased AT1-stimulated interleukin-
1 release from monocytes of hypertensive patients. tion, because monocytes do not express significant
amounts of B2 receptors (data not shown). We thereforeWe further analyzed the AT1-stimulated activation of
monocytes and determined the adhesion of monocytes focused on the AT1 receptor protein and detected the
monocytic AT1 receptor with AT1-specific antibodies into endothelial cells. Basal and angiotensin II-stimulated
monocyte adhesion of the patients was also significantly immunoblot (AbdAlla et al., 2000, 2001a, 2001b). The
monocytic AT1 receptor of the control individuals withincreased (Figures 1C and 1D). These findings are in
agreement with previous data demonstrating an in- an apparent molecular mass of Mr 75–85 kDa was
predominantly monomeric, as was the AT1 receptor ofcreased AT1 receptor-dependent activation of mono-
cytes in hypertension (Do¨rffel et al., 1999; 2001). transfected HEK cells (Figure 1F versus Figure 1E). In
contrast, a major proportion of the monocytic AT1 recep-
tor of the patients had a high molecular mass of 200Identification of Covalently Dimerized
AT1 Receptors kDa under the standard reducing conditions of SDS-
PAGE supplemented with urea (Figure 1F). N-terminalThe mechanism of the increased AT1-dependent mono-
cyte activation is not known. We assessed a relationship protein sequencing of the affinity-purified high molecu-
lar mass AT1 receptor isolated from patients exclusivelybetween enhanced AT1 activity and AT1 dimerization,
because the enhanced AT1 receptor responsiveness of yielded the N-terminal sequence of AT1, MILNSST (Fig-
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Figure 2. Intracellular Monocytic Factor XIIIA Transglutaminase Crosslinks AT1 Dimers
(A) Immunoblot detection of purified factor XIIIA (c) or of factor XIIIA expressed in HEK cells (HEK) with affinity-purified factor XIIIA-specific
antibodies. Mock-transfected cells served as a control.
(B) Monocytic factor XIIIA of the eight control individuals (control) and of the eight hypertensive patients (patients) used for the experiments
in Figure 1. The amount of the loaded protein was controlled by anti-G (lower panel). The lane marked with a is a specificity control
performed in the presence of the corresponding antigen used for immunization.
(C) Partial activation of factor XIIIA in the cytosolic fraction of monocytes by purified thrombin (/) followed by immunoblot detection.
(D and E) Basal (D) and thrombin-stimulated (E) monocytic factor XIIIA transglutaminase activity of the eight control individuals and of the
eight patients assessed by a [3H]putrescine incorporation assay (*p  0.01).
(F) Ionomycin (iono, 0.1 M, 8 hr) increased factor XIIIA transglutaminase activity of human monocytes in the absence and presence of
angiotensin II (ang).
(G) Upon factor XIIIA activation by ionomycin, angiotensin II (ang, applied for 8 hr as indicated) induced the appearance of crosslinked AT1
dimers in a concentration-dependent manner on moncytes of a control individual as determined in immunoblot with affinity-purified AT1-
specific antibodies (lanes 1–6). The AT1-specific antagonist losartan (antag., 5 M, lane 7 versus lane 8) or the transglutaminase inhibitors
monodansyl cadaverine (m., lane 10) and cystamine (c., lane 11) at 200 M suppressed the angiotensin II-induced formation of crosslinked
AT1 dimers (lane 12 versus lane 9).
(H) Monocytes of five patients with congenital factor XIIIA deficiency (FXIIIA-def) lack crosslinked AT1 dimers (lanes 1–5), while AT1 on monocytes
of six age-matched controls is predominantly dimeric upon activation by ionomycin and angiotensin II (iono/ang).
(I) Monocytes of factor XIIIA-deficient patients lack factor XIIIA, while factor XIIIA is detected in monocytes of the six control individuals. Equal
protein loading was controlled by probing with anti-G (lower panel).
ure 1G). For comparison, cell surface AT1 receptor pro- proteins by catalyzing the formation of stable amide
bonds between proteins (Dutton and Singer, 1975). Thetein levels were not significantly different between pa-
tients and controls, as determined in immunoblot (Figure predominant transglutaminase of monocytes is factor
XIIIA (Muszbek et al., 1988). We determined monocytic1F) and by binding assay (24.7 4 fmol/mg protein, n
8; and 22.8  4.2 fmol/mg protein, n  8; of patients factor XIIIA in immunoblot by factor XIIIA-specific anti-
bodies (Figures 2A and 2B). Monocytic factor XIIIA pro-and controls, respectively; data not shown). Altogether,
the apparent molecular mass in SDS-PAGE and the de- tein levels of hypertensive patients were moderately
(1.6-fold) increased (Figure 2B). In agreement with pre-termined AT1 sequence point to a covalently bonded
AT1 receptor homodimer in patients. vious findings (Muszbek et al., 1988), the intracellular
factor XIIIA was not activated by thrombin cleavage,
because the electrophoretic mobility of the thrombin-Monocytic Factor XIIIA Transglutaminase
We analyzed the mechanism underlying the formation cleaved factor XIIIA was clearly distinguished from the
intact factor XIIIA of monocytes (Figure 2C). Neverthe-of covalently bonded AT1 receptor homodimers to reveal
its possible involvement in the enhancement of AT1- less, monocytic factor XIIIA of the patients displayed a
markedly increased (3- to 4-fold) basal transglutaminasedependent monocyte activation. The covalently dimer-
ized AT1 receptors were stable under reducing condi- activity compared to that of the control individuals (Fig-
ure 2D). For comparison, the monocytic factor XIIIA ac-tions of SDS-PAGE, excluding the possibility of disulfide
bond formation. Receptor dimers can also be stabilized tivity after thrombin cleavage was increased only 1.6-
fold, confirming immunoblot results (Figure 2E versusby crosslinking (AbdAlla et al., 2000), and transglutami-
nases mediate enzymatic crosslinking of membrane Figure 2B). Thus, hypertensive patients displayed mark-
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Figure 3. Angiotensin II Generation of Mono-
cytes
(A) Monocytic ACE activity of the eight hyper-
tensive patients and of the eight control indi-
viduals, as determined by the conversion of
angiotensin I into angiotensin II and quantifi-
cation of angiotensin II (ang) by radioimmu-
noassay. The ACE inhibitor captopril (ACEI,
20 M) suppressed monocytic angiotensin II
generation (*p  0.01 versus controls).
(B) Monocytic angiotensin II of the eight pa-
tients and of the eight controls as determined
in immunoblot with affinity-purified angioten-
sin II-specific (anti-ang) antibodies. The protein amount was controlled by probing with anti-G. The lane marked with a is a specificity
control performed in the presence of the antigen used for immunization.
edly increased monocytic factor XIIIA activity and a XIIIA is the predominant transglutaminase of mono-
cytes, which crosslinks AT1 receptors following angio-modest rise of factor XIIIA protein levels.
tensin II stimulation.
Mechanism of AT1 Crosslinking
Angiotensin II Generation of MonocytesDoes activated factor XIIIA account for the appearance
The formation of crosslinked AT1 dimers requires acti-of crosslinked AT1 receptor dimers in humans? We acti-
vated factor XIIIA and angiotensin II. Searching for thevated the intracellular factor XIIIA of monocytes from a
source of angiotensin II, we determined angiotensin IIhealthy individual by a calcium ionophore (Muszbek et
plasma levels. In line with previous observations (Dug-al., 1995). While the ionophore increased basal transglu-
gan et al., 1992), plasma levels of intact angiotensin IItaminase activity (Figure 2F versus Figure 2D), the sole
were not significantly different between patients andactivation of factor XIIIA was not sufficient to induce
controls (7.2  4.6 pM, n  8; and 6.8  2.8 pM, n  8;crosslinking of AT1 receptors (Figure 2G, lane 2 versus
respectively). In contrast, monocytes of hypertensivelane 1). We previously reported that angiotensin II in-
patients generated increased levels of angiotensin IIduces formation of noncovalently bound AT1 receptor
from the precursor angiotensin I (Figure 3A). The mono-homodimers, which can be stabilized by the addition
cytic angiotensin-converting enyzme (ACE) seemed re-of a synthetic crosslinker (AbdAlla et al., 2001b). The
sponsible for the enhanced angiotensin II formation, be-application of angiotensin II did not significantly affect
cause the ACE inhibitor captopril markedly suppressedfactor XIIIA activity (Figure 2F) and did not induce the
the production of angiotensin II (Figure 3A). Increasedappearance of crosslinked AT1 dimers (Figure 2G, lane
ACE activity may also account for an increased local3). In contrast, the concomitant application of ionophore
production of angiotensin II in vivo, because elevatedand angiotensin II induced the formation of crosslinked
levels of immunoreactive angiotensin II were also pres-AT1 dimers in a concentration-dependent manner (Fig-
ent in/on monocytes freshly isolated from patients (Fig-ure 2G, lanes 4–6). The formation of crosslinked AT1
ure 3B, upper panel; the lower panel shows equal proteindimers was suppressed either by application of the AT1-
loading by detecting G). Thus, there is an increasedspecific antagonist losartan (Figure 2G, lane 7 versus
ACE-dependent angiotensin II production and storagelane 8) or by the transglutaminase inhibitors monodansyl
by monocytes of hypertensive patients.cadaverine and cystamine (Figure 2G, lanes 10 and 11
versus lanes 9 and 12). These findings suggest that AT1
receptor activation and (factor XIIIA) transglutaminase Crosslinking of AT1 Dimers in HEK
Cells and In Vitroactivity are required for AT1 receptor dimerization and
crosslinking. Factor XIIIA and angiotensin II mediate the formation
of crosslinked AT1 receptors in monocytes. We nextTo further analyze whether factor XIIIA crosslinks
monocytic AT1 receptors, we compared monocytes of assessed the formation of crosslinked AT1 dimers in AT1-
transfected HEK cells without or with coexpression offactor XIIIA-deficient patients with those of healthy age-
matched controls. Under basal conditions, the mono- factor XIIIA (Figures 4A and 4B). Angiotensin II induced
the appearance of crosslinked AT1 dimers in a concen-cytic AT1 receptor of factor XIIIA-deficient patients and
of control individuals was not different, appearing in tration-dependent manner of factor XIIIA-expressing
cells preactivated with ionomycin (Figure 4B). Moreover,both groups as a monomer (data not shown). However,
monocytes of the factor XIIIA-deficent patients showed purified and preactivated factor XIIIA was capable to
crosslink enriched angiotensin II-induced AT1 dimersalso a monomeric AT1 band upon application of the
factor XIIIA activating agent ionomycin and of angioten- in vitro similarly to the synthetic crosslinker DST (Figure
4C, lanes 1–3), while a catalytic inactive factor XIIIAC314Asin II, whereas monocytes of the healthy individuals dis-
played high levels of crosslinked AT1 dimers (Figure 2H). mutant had no effect (Figure 4C, lanes 4 and 5). In con-
trast, coexpressed tissue transglutaminase (TG2) (Fig-Accordingly, the monocytic factor XIIIA protein was only
detectable in monocytes of the healthy individuals but ure 4D, lanes 2 and 3 versus lane 1) preactivated with
ionomycin did not efficiently stabilize angiotensin II-was absent in factor XIIIA-deficient patients (Figure 2I).
Together, these findings indicate that activated factor induced AT1 dimers in HEK cells (Figure 4D, lanes 4–6).
Crosslinked AT1 Receptor Dimers
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Figure 4. Enhanced Signaling and Desensitization of Crosslinked AT1 Dimers
(A) Immunoblot detection of factor XIIIA (anti-FXIIIA) in mock-transfected control cells (lane 1, ) and in HEK cells expressing factor XIIIA
(lane 2, FXIIIA).
(B) Expression of factor XIIIA in HEK cells and activation by 0.1 M ionomycin for 8 hr did not efficiently trigger AT1 receptor dimerization
compared to cells expressing AT1 in the absence of factor XIIIA (lane 2 versus lane 1). Increasing concentrations of angiotensin II (8 hr) induced
the appearance of crosslinked AT1 dimers in cells expressing AT1 and ionomycin-preactivated factor XIIIA (lanes 3–6).
(C) In vitro crosslinking of enriched AT1 receptors by purified and preactivated factor XIIIA (FXIIIA*) in the absence (lane 1) or presence (lane
2) of 10 nM angiotensin II (ang). For comparison, angiotensin II-induced AT1 dimers were crosslinked with DST (lane 3). As a control, the
catalytically inactive FXIIIAC315A mutant (FXIII-mut) had no effect either in the absence or presence of angiotensin II (lanes 4 and 5).
(D) Immunoblot detection of transglutaminase 2 (TG) in TG2-transfected HEK cells (lanes 2 and 3) compared to mock-transfected cells (lane
1). Expression and activation (0.1 M ionomycin, 8 hr) of TG2 did not efficiently crosslink AT1 dimers upon angiotensin II (ang, 8 hr) stimulation
(lanes 4–6).
(E) Inositol phosphate levels of HEK cells expressing crosslinked AT1 dimers (CD) compared to control cells expressing noncrosslinked AT1
(con). HEK cells expressing factor XIIIA and AT1 receptors were pretreated either without (con) or with 0.1 M ionomycin and 10 nM angiotensin
II for 8 hr (CD), loaded with [3H]inositol, washed, and stimulated for 20 min with increasing concentrations of angiotensin II as indicated; total
inositol phosphates were extracted and quantified and are presented as c.p.m. Data are the mean  SEM, n  6.
(F) Angiotensin II-stimulated (10 nM) inositol phosphate levels of HEK cells expressing AT1, and FXIIIA or TG2 as indicated. Cells were
preincubated with ionomycin and angiotensin II (8 hr) as in (E). Data are expressed as % of control, i.e., the angiotensin II-stimulated increase
in inositol phosphate levels of AT1-expressing cells (100%). Data are the mean  SEM, n  6; *p  0.01.
(G) Determination of cell surface AT1 receptors of HEK cells expressing noncrosslinked AT1 receptors (panels 1 and 2; con) or crosslinked
AT1 dimers (panels 3 and 4; CD). Crosslinked AT1 dimers were induced as in (E), and cell surface AT1 receptors were quantified by FACS using
AT1-specific antibodies. Cells were treated without (panels 1 and 3) or with (panels 2 and 4) 100 nM angiotensin II for 30 min at 37	C (intern.).
Angiotensin II led to a moderate decrease in the fluorescence intensity of cells expressing noncrosslinked AT1 receptors (panel 2) while
markedly decreasing that of cells expressing crosslinked AT1 dimers (panel 4) indicative of enhanced receptor internalization of crosslinked
AT1 dimers.
(H) Angiotensin II- and endothelin-stimulated increase in [Ca2]i of HEK cells grown on glass cover slips. Cells expressed factor XIIIA and
noncrosslinked AT1 (con, panels 1–3) or crosslinked AT1 dimers induced as in (E) (CD, panels 4–6). Cells were washed, loaded with fura-2,
and stimulated as indicated with 10 nM angiotensin II (ang, panels 1, 2, 4, and 5) or endothelin-1 (ET, panels 3 and 6) without (panels 1 and
4) or with prior treatment with 100 nM angiotensin II for 5 min at 37	C (followed by washing) to induce AT1 desensitization (desensitized,
panels 2, 3, 5, and 6).Single experiments are representative of three independent experiments, each with similar results.
This finding may either reflect that AT1 is a poor substrate increased cellular inositol phosphate levels compared
to noncrosslinked AT1 receptors upon stimulation withof TG2 due to different substrate specificities of factor
different concentrations of angiotensin II (Figure 4E).XIIIA and TG2 (Gorman and Folk, 1980), or that receptor-
Moreover, expression and ionomycin activation of TG2stimulated GTP loading inhibited TG2 activity in cells
did not lead to significant enhancement of angiotensin(Zhang et al., 1998). Altogether, factor XIIIA crosslinks
II-stimulated inositol phosphate signaling (Figure 4F),AT1 receptor dimers in transfected HEK cells, in native
consistent with the result of Figure 4D. Increased signal-monocytes, and in vitro.
ing of the crosslinked AT1 dimers was accompanied by
an enhanced G
q/11 activation, as determined by the AT1
Enhanced Signaling and Desensitization receptor-stimulated GTPS binding to G
q (cf. Figure 5C).
of Crosslinked AT1 Dimers The amount of expressed AT1 receptors in transfected
We measured the phospholipase C-dependent increase HEK cells was controlled by fluorescence-activated cell
in cellular inositol phosphate levels predominantly medi- sorting (FACS) analysis using AT1-specific antibodies.
ated by the AT1-stimulated activation of G
q/11. In this The analysis revealed similar staining of cells expressing
noncrosslinked AT1 receptors and crosslinked AT1 di-assay, crosslinked AT1 dimers produced almost 3-fold
Cell
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mers (Figure 4G, panels 1 and 3). Application of a satu-
rating concentration of angiotensin II triggered AT1 re-
ceptor internalization, as reflected by a decrease in cell
surface fluorescence intensity (Figure 4G). Internaliza-
tion of the crosslinked AT1 dimers was significantly in-
creased compared to the noncrosslinked AT1 receptors
(Figure 4G, panel 4 versus panel 2).
The G
q/11-dependent signal transduction of the
crosslinked AT1 dimers was further analyzed by measur-
ing the angiotensin II-stimulated transient rise in intra-
cellular calcium, [Ca2]i. In agreement with Figure 4E, the
crosslinked AT1 dimers displayed markedly increased
signaling compared to noncrosslinked AT1 receptors
(Figure 4H, panel 4 versus panel 1). Receptor activation
induces receptor desensitization, which is visible by a
decreased receptor-stimulated response. Angiotensin
II-prestimulated cells revealed partial desensitization of
noncrosslinked AT1 receptors in contrast to full desensi-
tization of crosslinked AT1 dimers as measured by the
angiotensin II-stimulated calcium transient (Figure 4H,
panel 5 versus panel 2). As a control, cells expressing
either noncrosslinked or crosslinked AT1 receptors were
equally responsive to endothelin-1 with or without prior
desensitization of AT1 (Figure 4H, panels 3 and 6; and
data not shown). Thus, crosslinked AT1 dimers display
enhanced G
q/11-stimulated signaling, increased inter-
nalization, and desensitization.
Glutamine315 in the Cytoplasmic Side of AT1
Is a Target of Factor XIIIA
Transglutaminases catalyze the displacement of amide
ammonia at the  position in glutamine by replacing it
with an  amino group from a suitable lysine. An amine
acceptor glutamine of the AT1 receptor for factor XIII-
mediated crosslinking was determined by site-directed
mutagenesis. While removal of the extracellularly lo-
cated glutamines in AT1 did not affect the formation of
crosslinked AT1 receptor dimers (Figure 5A, lane 2 ver-
Figure 5. Glutamine315 of the AT1 Receptor Is a Target of Factor XIIIA
sus lane 1), exchange of glutamine315 significantly de-
creased the amount of crosslinked AT1 dimers formed
upon angiotensin II stimulation in the presence of acti-
vated factor XIIIA (Figure 5A, lane 3). As a control, AT1Q315A
(A) Mutated AT1Q315A receptor is not a target of factor XIIIA, while was capable to form homodimers upon angiotensin II
wild-type AT1, AT1Q15/257/267A (AT1QexA), and AT1Q229A form crosslinked stimulation, as assessed in immunoblot after stabiliza-
dimers as determined in immunoblot of angiotensin II-stimulated
tion of AT1Q315A dimers with the synthetic crosslinker DSTHEK cells expressing the indicated AT1 receptor and ionomycin-
(data not shown). As an additional control, removal ofpreactivated factor XIIIA.
(B) Ionomycin-preactivated intracellular factor XIIIA did not enhance glutamine229 also did not markedly alter AT1 receptor
the angiotensin II-stimulated (10 nM) inositol phosphate signal medi- dimerization (Figure 5A, lane 4). Together, these findings
ated by AT1Q315A, which is not a target of factor XIIIA-mediated cross- suggest that glutamine315 in the cytoplasmic tail of the
linking, while factor XIIIA-dependent crosslinking of wild-type AT1, AT1 receptor is a target of factor XIII-mediated cross-of AT1QexA, and of AT1Q229A enhanced AT1-stimulated signaling com- linking.pared to similarly pretreated control cells expressing the indicated
Activated factor XIIIA led to enhanced signaling of thereceptor in the absence of factor XIIIA (column 1, #, 100%). Data
are the mean  SEM, n  6; *p  0.01. wild-type AT1 receptor and of the AT1 receptor mutants,
(C) Factor XIIIA-crosslinked AT1 dimers (CD) stimulate enhanced which were targets of factor XIIIA (Figure 5B). In contrast,
GTPS binding to G
q as determined with membranes (20 g/point) activated factor XIIIA did not affect signaling of the
of angiotensin/ionomycin-pretreated (8 hr) HEK cells expressing AT1 AT1Q315A mutant that was not crosslinked by factor XIIIA(left panel) or AT1Q315A (right panel) and FXIIIA as indicated. The spe- (Figure 5B). In line with this finding, the receptor-stimu-cific angiotensin II-stimulated (100 nM) GTPS binding to G
q is
lated G
q activation mediated by the crosslinked wild-presented. Receptor expression levels (100 fmol/mg protein),
FXIIIA and G
q levels—as applicable—were comparable. Data are type AT1 dimers was significantly enhanced compared
the mean  SD, n  6.
(D) The angiotensin II-stimulated calcium transient of fura-2-loaded
and angiotensin/ionomycin-pretreated (8 hr) HEK cells expressing
AT1Q315A and factor XIIIA as indicated. Desensitization of AT1Q315A was Cell surface AT1Q315A receptors were determined by FACS analysis
induced by angiotensin II (100 nM; right panels). without (left panels) or with (right panels) pretreatment with angio-
(E) Receptor internalization of AT1Q315A is not affected by factor XIIIA. tensin II to induce receptor internalization.
Crosslinked AT1 Receptor Dimers
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Figure 6. ACE Inhibitor Therapy of Hypertensive Patients Normalizes the Monocytic AT1 System and Covalent AT1 Dimerization
(A) Immunoblot detection of monocytic angiotensin II of eight hypertensive patients before (patients) and after 3 months of ACE inhibitor
treatment (treated).
(B) Monocytic AT1 receptor detection in immunoblot with affinity-purified AT1-specific antibodies of eight patients before (patients) and after
(treated) ACE inhibitor treatment.
(C) ACE inhibitor treatment decreased elevated monocytic factor XIIIA levels of the eight patients as determined in immunoblot. Lanes marked
with a (A–C) are specificity controls with immunoblots performed in the presence of the corresponding antigens used for immunization. The
protein amount was controlled in the lower panels by probing with anti-G (A) or anti-G (C).
(D) Basal monocytic factor XIIIA activity of patients before and after ACE inhibitor treatment as assessed by active-site SH-labeling with
[14C]iodoacetamide followed by immunoprecipitation (IP) with affinity-purified factor XIIIA-specific antibodies and fluorography (upper panel).
The lower panel controls immunoprecipitated monocytic factor XIIIA (IP) by factor XIIIA-specific antibodies in immunoblot (IB).
(E) Basal monocytic factor XIIIA transglutaminase activity of patients before and after ACE-inhibitor therapy as determined by [3H]putres-
cine incorporation.
(F and G) Basal and angiotensin II (ang)-stimulated monocyte adhesiveness of patients before and after ACE-inhibitor therapy. Monocytes
were pretreated with 5 M losartan ( antag.) as indicated (*p  0.02 versus treated).
to noncrosslinked AT1 receptors, but GTPS binding to sive crosslinked AT1 dimers of monocytes. To explore
the importance of this relationship in vivo, we analyzedG
q mediated by the AT1Q315A receptor mutant was not
significantly enhanced under similar conditions (Figure monocytes of hypertensive patients before and after
3 months of an ACE inhibitor-based antihypertensive5C). Likewise, factor XIIIA did not affect calcium signal-
ing and internalization of the AT1Q315A receptor mutant therapy. ACE inhibition significantly decreased the ele-
vated monocytic angiotensin II levels (Figure 6A) and(Figures 5D and 5E). Together, these findings further
confirm that crosslinking of AT1 receptor dimers leads to reduced the pathologically elevated levels of cross-
linked AT1 dimers (Figure 6B). Concomitantly, factorenhanced AT1 receptor-stimulated G protein activation,
signaling, and desensitization. XIIIA protein levels and basal factor XIIIA activity were
decreased as determined in immunoblot or by active-
site SH labeling and by [3H]putrescine incorporation,ACE Inhibition Normalizes the Monocytic
AT1 Receptor System respectively (Figures 6C–6E). Moreover, the AT1-depen-
dent monocyte adhesion of patients normalized uponThe interplay between activated factor XIIIA and angio-
tensin II is essential for the production of hyperrespon- ACE inhibition (Figures 6F and 6G). Together, these find-
Cell
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Figure 7. Crosslinked AT1 Dimers in ApoE-Deficient Mice
(A) Treatment of MSCV-transduced ApoE/ control mice (ApoE/) with ACE inhibitor captopril (ACEI) or retrovirus-mediated expression
of a factor XIIIA inhibitor (FXIII-I) decreased the amount of crosslinked AT1 dimers of monocytes from 26-week-old mice.
(B) Basal factor XIIIA activity of monocytes from 26-week-old MSCV-transduced control (ApoE/), ACE inhibitor-treated (ACEI), or factor
XIIIA inhibitor-expressing (FXIII-I) ApoE/ mice (n  8).
(C and D) Quantification (C) of aortic root lesion area of 26-week-old MSCV-transduced control (ApoE/), ACE inhibitor-treated (ACEI), or
factor XIIIA inhibitor-expressing (FXIII-I) ApoE/ mice (n 8). Representative hematoxylin-eosin-stained sections (original magnification50)
representing the mean lesion area of each group (D).
(E) Immunoblot of factor XIIIA (FXIIIA) and of the factor XIIIa inhibitor (N73–D98; FXIII-I) of monocytes from 26-week-old control (ApoE/), ACE
inhibitor-treated (ACEI), or MSCV-FXIII-I-transduced (FXIII-I) ApoE/ mice.
(F) Body weight, plasma cholesterol, and systolic blood pressure of the three groups.
(G) Immunohistochemical staining of monocytes/macrophages in aortic valve sections of 16-week-old MSCV-transduced control (ApoE/;
panel 1), ACE inhibitor-treated (ACEI; panel 2), or MSCV-FXIII-I-transduced (FXIII-I; panel 3) ApoE/ mice with MOMA-2-specific antibodies
following antigen retrieval (original magnification 600). Panel 4 shows a section of ApoE/ mice stained with control IgG. A representative
section is shown for each group.
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ings strongly suggest that ACE-dependent angiotensin cytes/macrophages in aortic root sections with MOMA-
2-specific antibodies (Figure 7G). Quantitative PCRII generation is causally involved in the formation of
factor XIIIA-crosslinked AT1 receptor dimers on mono- tracking the retrovirus-derived hygromycin phospho-
transferase (Hyg) gene in the aortic DNA confirmed thecytes of hypertensive patients. Moreover, the appear-
ance of the crosslinked AT1 dimers may contribute to decrease in the recruitment of blood cells into the aorta
of ACE- or factor XIII inhibitor-treated mice (Figure 7H,an enhanced AT1-dependent monocyte adhesiveness.
upper and middle panels). As a control, Southern blot
analysis of the genomic DNA of circulating blood cellsInhibition of ACE or of Intracellular Factor XIIIA
from the three treatment groups revealed comparableof Blood Cells Suppresses AT1 Receptor
provirus integration of MSCV or MSCV-FXIII-I (FigureDimerization and Symptoms of Atherosclerosis
7H, lower panel). Concomitantly to the suppression ofin ApoE-Deficient Mice
blood cell infiltration of the aorta, mean aortic root lesionSince enhanced monocyte adhesion is a key feature of
area was also significantly reduced upon ACE or factoratherogenesis, we assessed the AT1 system of hyper-
XIIIA inhibition (63,480  10,930 m2, 17,480  3,650cholesterolemic ApoE-deficient (ApoE/) mice, which
m2, and 34,670  7,530 m2 of control, ACE or factorserve as a model of atherosclerosis. Monocytes of
XIIIA inhibitor-treated 16-week-old ApoE/ mice, re-ApoE/ mice displayed increased levels of crosslinked
spectively; n  8;  SD; p  0.01). Thus, angiotensinAT1 receptor dimers at 6 weeks of age (data not shown)
II-triggered and factor XIIIA-crosslinked AT1 dimers ofand at the end of the observation period at 26 weeks
circulating blood cells are related to the appearance of(Figure 7A). Treatment for 10 weeks with the ACE inhibi-
symptoms of atherosclerosis in this experimental model.tor captopril significantly decreased the amount of
crosslinked AT1 dimers on monocytes and suppressed
the monocytic factor XIIIA activity compared to un- Discussion
treated ApoE/ mice (Figures 7A and 7B). In agreement
with the antiatherosclerotic effect of ACE inhibitors in We herein identify hyperresponsive crosslinked angio-
tensin II-induced AT1 receptor homodimers, which arethis model (Hayek et al., 1998), the mean lesion area
of the aortic root was substantially reduced upon ACE covalently bonded by the transglutaminase activity of
intracellular factor XIIIA. This previously unrecognizedinhibition (Figures 7C and 7D).
To assess the involvement of factor XIIIA, we inhibited species of crosslinked receptor homodimers is distin-
guished from dissociable constitutive receptor clusters/the intracellular factor XIIIA activity of blood cells in vivo
by retroviral transduction of a factor XIIIA inhibitor oligomers/dimers or monomers by covalent linkage of
two receptor molecules. Considering the finding that(Achyuthan et al., 1993). The expression of the factor
XIIIA inhibitor was demonstrated in immunoblots of two receptors could interact with one G protein (Baneres
and Parello, 2003), a unique nondissociable entity ofbone marrow cells, of macrophages, and of circulating
monocytes of bone marrow-transplanted ApoE/ mice two crosslinked AT1 receptors may provide a kinetically
favorable interface for interaction with the G proteintransduced with the factor XIIIA inhibitor-encoding ret-
rovirus (data not shown and Figure 7E). Expression of compared to two individual receptors or to a dissociable
receptor complex, thereby accounting for enhanced ac-the factor XIII inhibitor in ApoE/ mice was detected
as early as 3 weeks after bone marrow transplantation tivation and signaling.
Increased levels of hyperresponsive crosslinked AT1and persisted until the end of the observation period at
26 weeks (data not shown). The factor XIIIA inhibitor dimers were present on monocytes of patients with the
atherogenic risk factor hypertension and correlated withsignificantly decreased the levels of crosslinked AT1 di-
mers and suppressed the factor XIIIA activity of mono- an increased angiotensin II-dependent monocyte acti-
vation and adhesiveness. An enhanced monocyte ad-cytes (Figures 7A and 7B). Concomitantly, the athero-
sclerotic lesion area was significantly reduced (Figures herence to the endothelium at sites predisposed to ath-
erosclerosis is one of the earliest detectable cellular7C and 7D). Captopril or the factor XIIIA inhibitor did
not affect plasma cholesterol level or body weight, while responses in atherogenesis leading to the formation of
atherosclerotic lesions (Faggioto et al., 1984; Gerrity etsystolic blood pressure was decreased by captopril (Fig-
ure 7F). al., 1985). Monocyte recruitment into the artery involves
not only an alteration of the arterial wall but also requiresIn agreement with the enhanced AT1-dependent
monocyte adhesiveness of atherosclerosis-prone pa- functional changes in the circulating monocyte, with a
mutual exchange of activating stimuli between mono-tients (cf. Figures 1 and 6), monocyte/macrophage infil-
tration of the aorta of 16-week-old ApoE/ mice was cytes and endothelium (Gerrity et al., 1985). In this con-
text, the present work may delineate a mechanism ac-also significantly decreased upon ACE or factor XIIIA
inhibition, as determined by immunostaining of mono- counting for functional changes of monocytes at the
(H) Quantitative assessement of blood cell recruitment into the aorta of 16-week-old MSCV-transduced control (ApoE/), MSCV-transduced
ACE inhibitor-treated (ACEI), or MSCV-FXIII-I-transduced (FXIII-I) ApoE/ mice measured by quantitative PCR (QT-PCR) amplifying the
hygromycin phosphotransferase gene of the transduced MSCV (arbitrary units, upper panel, n  8). Representative autoradiography of the
PCR products obtained from serial dilutions of the internal standard (Std, 220 bp) and a constant amount of aortic DNA (Hyg, 180 bp) from
an individual mouse of each group (middle panel). Southern blot of KpnI-digested genomic DNA from circulating blood cells of five mice of
each group hybridized with a Hyg probe shows fragments of 3.3 and 3.4 kb indicative of comparable levels of MSCV or MSCV-FXIII-I
proviruses (lower panel). Data are the mean  SD, *p  0.01.
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Experimental Proceduresonset of atherogenesis, which is based on the appear-
ance of hyperactive crosslinked AT1 receptor dimers. In
Cell Culture and Functional Assaysline with such a hypothesis is the finding that high levels
HEK cells were cultured and transfected with the indicated cDNAs;
of crosslinked AT1 dimers were present on monocytes mutants were generated by PCR; and cellular inositol phosphate
of hypercholesterolemic ApoE-deficient mice, and in- levels, [Ca2]i, and the AT1 receptor-stimulated increase in the
hibition of angiotensin II generation or of intracellular GTPS binding of G
q were determined as described (AbdAlla et
al., 2000; Lorenz et al., 2003). All solutions and chemicals used infactor XIIIA activity suppressed the appearance of
monocyte isolation and activation procedures were endotoxin-freecrosslinked AT1 receptor dimers and symptoms of ath-
(endotoxin0.008 ng/ml). Human or mouse peripheral blood mono-erosclerosis.
cytes were isolated from heparin- or EDTA-anticoagulated blood
Formation of crosslinked AT1 dimers requires the acti- diluted with PBS by density gradient centrifugation through Ficoll-
vation of the angiotensin II-AT1 system and of factor Paque or Optiprep followed by plastic adherence, or by Nycoprep
XIIIA. A wealth of data demonstrated the increased ac- density gradients. Cell viability was98%, as determined by trypan
blue exclusion and propidium iodide staining, and monocyte puritytivity of local ACE-dependent angiotensin II-generating
as determined by immunofluorescence staining of cell-specific anti-systems in hypertension and vascular disease (Dzau,
gens (CD14/CD45, CD3, CD19, CD68, and CD163) was 80%.2001), and pressure as well as shear stress or inflamma-
Monocyte release of interleukin-1 into culture supernatant wastory stimuli directly induces the expression of ACE (Gos-
determined by ELISA (R&D Systems), transglutaminase activity was
gnach et al., 2000; Lazarus et al., 1994; Schunkert et al., assessed in cell lysates by [3H]putrescine incorporation assay (Mus-
1990). In agreement with these observations, monocytic zbek et al., 1995), and adhesion of monocytes to endothelial cells
ACE activity and/or angiotensin II generation were in- was determined as described (Do¨rffel et al., 1999). The intraassay
variations were less than 5%, and the day-to-day variation in onecreased in patients with the atherogenic risk factor hy-
subject was less than 10%. Group data are expressed as means pertension and in hypercholesterolemic ApoE-deficient
SD. Mean values were compared with the use of paired or unpairedmice. Thus, activation of the monocytic angiotensin II-
Student’s t tests, as appropriate. P values 0.05 were considered
AT1 system may be triggered by vascular inflammation, significant.
which develops as a consequence of persisting athero-
genic risk factors such as hypertension or hypercholes- Fluorescence-Activated Cell Sorting
terolemia. In addition to activation-dependent receptor Cell surface AT1 receptors of transfected HEK cells were determined
dimerization, constitutive receptor clustering and dimer- by FACS using affinity-purified AT1-specific antibodies raised
against an antigen corresponding to the receptor’s third extracellu-ization have been reported (Fotiadis et al., 2004), and
lar loop, as described (Quitterer et al., 1999).the concept of a dynamic interplay between receptor
clustering and ligand-induced receptor rearrangement
Protein Detection in Immunoblot and Protein Sequencingis emerging (Franco et al., 2003). However, the amount
AT1 receptor monomers and dimers of monocytes and of HEK cellsof crosslinked AT1 dimers was negligible in vivo in the were determined in immunoblot with AT1-specific antibodies as de-
absence of angiotensin II. This finding could reflect (1) scribed (AbdAlla et al., 2000, 2001a, 2001b). The intraassay variation
that constitutive AT1 receptor clusters/dimers are not for AT1 receptor detection and the day-to-day variation in one sub-
ject were less than 10%. Tissue levels of the factor XIIIA proteinabundant in vivo, and/or (2) that structural differences
were determined in immunoblot with factor XIIIA-specific antibod-between constitutive receptor clusters/dimers and ago-
ies. Specificity and crossreactivity of the antibodies with human ornist-induced dimers preclude covalent modification by
mouse factor XIIIA were confirmed in immunoblot. Angiotensin IIfactor XIIIA.
levels of monocytes were determined in immunoblot after Tricine-
Besides enhancing the release of angiotensin II, ath- SDS-PAGE with angiotensin II-specific antibodies displaying mini-
erogenic risk factors may also induce factor XIIIA (Ma mal crossreactivity to angiotensin I (1%). As controls, protein levels
and Liew, 2003). On the other hand, the sole accumula- of G and G proteins were determined with G- or G-specific anti-
bodies.tion of factor XIIIA protein is not necessarily associated
Monocytes were isolated from hypertensive patients for amino-with its crosslinking activity (Zhang et al., 1998). The
terminal protein sequencing of the crosslinked AT1 dimer. Afterincreased factor XIIIA activity may therefore be the major
membrane preparation, the AT1 receptor was solubilized and affinityevent contributing to crosslinking of AT1 dimers. Activa- purified by lectin- and immuno-affinity chromatography. Purified
tion of intracellular factor XIIIA can be mediated by an AT1 receptors were desalted and concentrated using a Centricon
altered ion homeostasis (Polga´r et al., 1990) and/or by filtration unit (exclusion limit 100,000 Da). Proteins were subjected
oxidative stress. Increased sodium and calcium levels to SDS-PAGE, transferred to a PVDF membrane, and analyzed on
an ABI 494A Procise HT (IBA GmbH, Goettingen, Germany).are characteristic features of hypertension and vascular
disease (Caimi et al., 1997; Postnov and Orlov, 1985),
Patientsand the atherosclerosis-promoting effect of oxidative
Monocytes were isolated from the peripheral blood of 16 patientsstress is well known. Thus, crosslinked AT1 receptor
diagnosed with essential hypertension (eight males, 53  3 years,dimers of monocytes may reflect the concerted action
74  7 kg, total plasma cholesterol 176  13 mg/dL, systolic/dia-
of a panoply of different atherogenic stimuli. In line with stolic blood pressure of 178  7/103  5 mm Hg). Hypertensive
this conclusion is the finding that ACE inhibitor treatment patients responded to an ACE inhibitor-based antihypertensive ther-
of atherosclerotic mice suppressed the development apy (captopril 12.5 mg three times daily titrated to 25–50 mg three
of atherosclerosis and concomitantly normalized factor times daily plus—if required—thiazide diuretic to reach a target
blood pressure of 140/90 mm Hg), i.e., 3 months of antihyperten-XIIIA activity. Due to the long half-life of 5 days, the
sive therapy decreased blood pressure significantly (systolic/dia-crosslinked AT1 dimers seem to be barely affected by
stolic bp 134  5/83  5 mm Hg). Monocytes were analyzed beforeshort-term changes of medication, diet, or lifestyle. In
any drug administration and after 3 months of therapy. Eight healthy
view of these data, it seems appropriate to propose that individuals served as controls matching the patients according to
crosslinked AT1 dimers sustain the process of athero- age, body weight, and gender (53 4 years, 72 7 kg, eight males,
genesis by chronic sensitization of circulating mono- total plasma cholesterol 175 12 mg/dL, systolic/diastolic bp 128
6/78  3 mm Hg). Patients (and controls) with other diseases orcytes.
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abnormal laboratory parameters, elevated LDL levels, or atheroscle- All animal experiments were reviewed and approved by the com-
mittees on animal research at the Universities of Cairo and of Ham-rosis were excluded.
Monocytes were isolated from the peripheral blood drawn for burg and were conducted in accordance with the NIH guidelines.
routine diagnosis of five patients with congenital factor XIIIA defi-
ciency and of six age-matched control individuals. Patients were References
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